Acute effects of aerosolized iloprost in COPD related pulmonary hypertension - a randomized controlled crossover trial
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 3887538
Author(s) Boeck, Lucas; Tamm, Michael; Grendelmeier, Peter; Stolz, Daiana
Author(s) at UniBasel Boeck, Lucas
Year 2012
Title Acute effects of aerosolized iloprost in COPD related pulmonary hypertension - a randomized controlled crossover trial
Journal PLoS ONE
Volume 7
Number 12
Pages / Article-Number e52248
Mesh terms Administration, Inhalation; Adult; Aerosols; Aged; Cross-Over Studies; Female; Humans; Hypertension, Pulmonary, physiopathology; Iloprost, therapeutic use; Male; Oxygen, metabolism; Pulmonary Disease, Chronic Obstructive, complications; Pulmonary Gas Exchange, drug effects
Abstract Inhaled iloprost potentially improves hemodynamics and gas exchange in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension (PH).; To evaluate acute effects of aerosolized iloprost in patients with COPD-associated PH.; A randomized, double blind, crossover study was conducted in 16 COPD patients with invasively confirmed PH in a single tertiary care center. Each patient received a single dose of 10 µg iloprost (low dose), 20 µg iloprost (high dose) and placebo during distinct study-visits. The primary end-point of the study was exercise capacity as assessed by the six minute walking distance.; Both iloprost doses failed to improve six-minute walking distance (p = 0.36). Low dose iloprost (estimated difference of the means -1.0%, p = 0.035) as well as high dose iloprost (-2.2%, p<0.001) significantly impaired oxygenation at rest. Peak oxygen consumption and carbon dioxide production differed significantly over the three study days (p = 0.002 and p = 0.003, accordingly). As compared to placebo, low dose iloprost was associated with reduced peak oxygen consumption (-76 ml/min, p = 0.002), elevated partial pressure of carbon dioxide (0.27 kPa, p = 0.040) and impaired ventilation during exercise (-3.0l/min, p<0.001).; Improvement of the exercise capacity after iloprost inhalation in patients with COPD-associated mild to moderate PH is very unlikely.; Controlled-Trials.com ISRCTN61661881.
Publisher Public Library of Science
ISSN/ISBN 1932-6203
edoc-URL http://edoc.unibas.ch/55860/
Full Text on edoc No
Digital Object Identifier DOI 10.1371/journal.pone.0052248
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/23300624
Document type (ISI) Journal Article, Randomized Controlled Trial
 
   

MCSS v5.8 PRO. 0.441 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
10/08/2020